Terapia con miRNAs en la enfermedad cardiovascular y envejecimiento: descubrimiento de nuevos candidatos
Year: 2020
Type: dissertation
Abstract: Cardiovascular diseases are, as of now, the main cause of death in the developed world. Aging is a main risk factor determining their development. In most of the cases, pharmacological treatments do not directly asses the problem and have only palliative effects, which decreases quality life of the patient and increase dependence on the treatment to follow a normal lifestyle. Therefore, looking for novel effective therapies to treat the cause of the disease will be crucial in the near future. microRNAs (miRNA) have been proved to be master regulators of many biological processes that take places in the cell, since they are capable of regulating gene expression. Studies in vitro and in vivo have associated dysregulation of the miRNAs expression with pathology in cardiovascular disease and aging, thus postulating them as possible therapeutic targets. As result, miRNAs-mimics and anti-miRs have emerged as a new promising therapeutic approach to correct gene expression alterations regulated by miRNAs that have been seen in disease. Here, a detailed revision of the application of miRNA-based therapies to treat CVD is made. Although, currently there are only 2 studies that have reached clinical trials, many preclinical studies have published encouraging results. Continuing previous work of the group BSICoS, a second aim of this master’s thesis is to develop tools for the study of the interaction of age-related miRNAs (BIO-AGEmiRNA) with their target genes in relation to cardiac function using human iPSC-derived cardiomyocytes. A inducible expression vector was created to be expressed mature miRNAs, specifically miR-4435, downstream of a fluorescent reporter gene. The vector was tested in vitro in HEK293 cells and proper expression of the reporter was observed. However, expression of the mature miR-4435, and therefore proper processing of the pre-miRNA, could not be confirmed due to technical issues. Future work will continue to validate the remaining BIO-AGE-miRNAs in vitro, first in HEk393 and then in iPSC-derived cardiomyocytes were the molecular mechanism and functionality of the BIO-AGEmiRNAs will be investigated. The developed vector will be most certainly a useful tool to complete this future work.
Authors: Pina Beltrán, Blanca, Ordovás Vidal, Laura, Ramos Marquès, Estel
Institution: Universidad de Zaragoza
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W6987600484
